Differentiation-dependent EBF1 Activity Determines CD22 Transcription and Leukemia Sensitivity to Inotuzumab Ozogamicin., PMID:40435412
Adult Acute Lymphoblastic Leukemia: 2025 Update on Diagnosis, Therapy, and Monitoring., PMID:40377367
Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ponatinib and blinatumomab., PMID:40369607
The evolving therapeutic revolution in adult acute lymphoblastic leukemia., PMID:40323723
Management of Adult Acute Lymphoblastic Leukemia: A Review., PMID:40310617
O-Cyanobenzaldehydes Irreversibly Modify Both Buried and Exposed Lysine Residues in Live Cells., PMID:40150802
Up-front blinatumomab improves MRD clearance and outcome in adult Ph- B-lineage ALL: the GIMEMA LAL2317 phase 2 study., PMID:40009490
Clearing MRD positivity with blinatumomab in pediatric B-cell acute lymphoblastic leukemia: insights from droplet digital PCR and flow cytometry., PMID:39668199
Philadelphia chromosome-positive or Philadelphia chromosome-like B-cell precursor acute lymphoblastic leukemia with multilineage involvement in pediatric patients: a report of two cases and literature review., PMID:39470068
SOHO State of the Art Updates and Next Questions | Approach to BCR::ABL1-Like Acute Lymphoblastic Leukemia., PMID:39217000
Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults., PMID:39047240
The BCR::ABL1 tyrosine kinase inhibitors ponatinib and nilotinib differentially affect endothelial angiogenesis and signalling., PMID:39009935
Asciminib stands out as the superior tyrosine kinase inhibitor to combine with anti-CD20 monoclonal antibodies for the treatment of CD20+ Philadelphia-positive B-cell precursor acute lymphoblastic leukemia in preclinical models., PMID:38841802
A Multicentre, Randomized Trial in Adults with de novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukaemia to Assess the Efficacy of Ponatinib versus Imatinib in Combination with Low-Intensity Chemotherapy, to Compare End of Therapy with Indication for Stem Cell Transplantation versus Tyrosine Kinase Inhibitor, Blinatumomab, and Chemotherapy in Optimal Responders, and to Evaluate Blinatumomab in Suboptimal Responders (GMALL-EVOLVE)., PMID:38754400
Asciminib Maintains Antibody-Dependent Cellular Cytotoxicity against Leukemic Blasts., PMID:38610966
Association of leukemic molecular profile with efficacy of inotuzumab ozogamicin in adults with relapsed/refractory ALL., PMID:38607410
A review of immunotargeted therapy for Philadelphia chromosome positive acute lymphoblastic leukaemia: making progress in chemotherapy-free regimens., PMID:38581291
Involvement of BCR::ABL1 in laminin adhesion of Philadelphia chromosome-positive acute lymphoblastic leukemia through upregulation of integrin α6., PMID:38577721
[Successful treatment with sequential blinatumomab/ponatinib in a patient with chronic myeloid leukemia presenting with a CD19-positive mixed phenotype blast phase]., PMID:39935224
How to Manage Philadelphia-Positive Acute Lymphoblastic Leukemia in Resource-Constrained Settings., PMID:38136329
Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL., PMID:38127722
Recent advances in therapies for primary myelofibrosis., PMID:37771602
Ph-like acute lymphoblastic leukemia in adults: understanding pathogenesis, improving outcomes, and future directions for therapy., PMID:37021793
Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the past., PMID:37003279
Prognostic value of cross-lineage expression of the myeloid-associated antigens CD13 and CD33 in adult B-lymphoblastic leukemia: A large real-world study of 1005 patients., PMID:36951610
The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades., PMID:36927623
Computational approaches for discovering significant microRNAs, microRNA-mRNA regulatory pathways, and therapeutic protein targets in endometrial cancer., PMID:36704357
Identification of CD203c as a New Basophil-Specific Flow-Marker in Ph+ Chronic Myeloid Leukemia., PMID:36611797
Ph+ ALL in 2022: is there an optimal approach?, PMID:36485090
Profiling of extracellular vesicles of metastatic urothelial cancer patients to discover protein signatures related to treatment outcome., PMID:35838333
Molecular Classification and Overcoming Therapy Resistance for Acute Myeloid Leukemia with Adverse Genetic Factors., PMID:35682627
Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusions., PMID:35650277
BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro., PMID:35551463
Molecular characterization and clinical outcome of B-cell precursor acute lymphoblastic leukemia with IG-MYC rearrangement., PMID:35484682
Anti-N-methyl-D-aspartate receptor encephalitis associated with chronic myelogenous leukemia, causality or coincidence? A case report., PMID:35461209
Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial., PMID:35358441
Identification of peripheral blood CD26+ leukemic stem cells has a potential role in the rapid diagnosis of chronic myeloid leukemia., PMID:35142061
The cure of leukemia through the optimist's prism., PMID:34614211
[B cell acute lymphoblastic leukemia therapy: an up to date overview]., PMID:34497196
Report of Canonical BCR-ABL1 Fusion in Glioblastoma., PMID:34485806
Comparison of Two Quantitative PCR-Based Assays for Detection of Minimal Residual Disease in B-Precursor Acute Lymphoblastic Leukemia Harboring Three Major Fusion Transcripts., PMID:34325057
Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms., PMID:34172894
Genetic Alterations and Therapeutic Targeting of Philadelphia-Like Acute Lymphoblastic Leukemia., PMID:34062932
Predictive value of tyrosine phosphatase receptor gamma for the response to treatment tyrosine kinase inhibitors in chronic myeloid leukemia patients., PMID:33893334
Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia with kinase fusions in Taiwan., PMID:33707599
PON2 subverts metabolic gatekeeper functions in B cells to promote leukemogenesis., PMID:33531346
Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia., PMID:33430292
Quantitative Tyrosine Phosphoproteomic Analysis of Resistance to Radiotherapy in Nasopharyngeal Carcinoma Cells., PMID:33328764
New approaches to the treatment of older adults with acute lymphoblastic leukemia., PMID:33256901
[Treatments for Philadelphia chromosome-positive acute lymphoblastic leukemia in the tyrosine kinase inhibitor era]., PMID:33162520
For research use only. Not for human or drug use.
